Bausch & Lomb
This article was originally published in The Tan Sheet
Executive Summary
Lens care sales fell 26%, U.S. revenues slipped 31% to $161.5 mil. during second quarter, firm announces July 19. Total sales down 9.1% to $414 mil. despite 31% improvement in Europe; net income plummets 80.3% to $6.8 mil. While predicting improved results for 2002, company notes it will continue to hold off on lens care promotions to reduce excess inventories to match actual consumer demand. Also, former Chairman/CEO William Waltrip to resume chairmanship as current Chair/CEO William Carpenter focuses on chief executive duties
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning